Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer

Clinical Breast Cancer

Volumn 9, Issue 3, 2009, Pages 173-177

  Ueno, Naoto T ^a   Souza, Jonas A De ^a,b   Booser, Daniel ^a   Nakayama, Kazutaka ^a   Madewell, John ^a   Wendt, Richard E ^a   Hortobagyi, Gabriel N ^a   Podoloff, Donald ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Autologous transplantation; Bone metastasis; Engraftment; Radiotherapy

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAMETHYLENE PHOSPHONIC ACID HOLIUM 166; HOLMIUM; RADIOPHARMACEUTICAL AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAKIS(METHYLENEPHOSPHONIC ACID); 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAKIS(METHYLENEPHOSPHONIC ACID); ORGANOPHOSPHORUS COMPOUND;

ACUTE TOXICITY; ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE METASTASIS; BREAST CANCER; CANCER CENTER; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEMORRHAGIC CYSTITIS; HUMAN; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PILOT STUDY; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TRISOMY 8; BONE; BONE TUMOR; BREAST TUMOR; DRUG EFFECT; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RADIATION EXPOSURE; TREATMENT OUTCOME;

ADULT; BONE AND BONES; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MIDDLE AGED; ORGANOPHOSPHORUS COMPOUNDS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 70350761922     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2009.n.028     Document Type: Article

References (15)

1. Ozols R F, Herbst RS, Colson YL, et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol 2007;25:146-62.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
3. Hortobagyi GN. Bone metastases in breast cancer patients. Semin Oncol 1991;18:11-5.
4. Solomayer E F, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 2000;59:271-8.
5. Body JJ. Breast cancer: bisphosphonate therapy for metastatic bone disease. Clin Cancer Res 2006;12:6258s-63s.
6. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metastasis Rev 1989;8:98-101.
7. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005;46(suppl 1):38S-47S.
8. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med 2004;45:1358-65.
9. Christoforidou AV, Saliba RM, Williams P, et al. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166) Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes. Biol Blood Marrow Transplant 2007;13:543-9.
10. Giralt S, Bensinger W, Goodman M, et al. 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials. Blood 2003;102:2684-91.
11. Breitz HB, Wendt RE, 3rd, Stabin MS, et al. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy. J Nucl Med 2006;47:534-42.
12. Breitz H, Wendt R, Stabin M, et al. Dosimetry of high dose skeletal targeted radiotherapy (STR) with 166Ho-DOTMP. Cancer Biother Radiopharm 2003;18:225-30.
13. Rajendran JG, Eary JF, Bensinger W, et al. High-dose 166Ho-DOTMP in myeloablative treatment of multiple myeloma: pharmacokinetics, biodistribution, and absorbed dose estimation. J Nucl Med 2002;43:1383-90.
14. Bayouth JE, Macey DJ, Kasi L P, et al. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma. J Nucl Med 1995;36:730-7.
15. Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22:2942-53.